Celsion (NASDAQ:CLSN) Downgraded to Sell at Zacks Investment Research

Zacks Investment Research cut shares of Celsion (NASDAQ:CLSN) from a hold rating to a sell rating in a research report sent to investors on Monday, Zacks.com reports.

According to Zacks, “Celsion is dedicated to the development and commercialization of oncology drugs including tumor-targeting treatments using focused heat energy in combination with heat activated drug delivery systems. Celsion has research, license or commercialization agreements with leading institutions such as the National Institutes of Health, Duke University Medical Center, University of Hong Kong, North Shore Long Island Jewish Health System. “

Several other equities analysts have also weighed in on the company. Oppenheimer set a $13.00 price objective on Alpine Immune Sciences and gave the company a buy rating in a report on Tuesday, March 19th. ValuEngine lowered Universal Electronics from a strong-buy rating to a buy rating in a report on Thursday, June 6th.

CLSN stock opened at $1.77 on Monday. The company has a market capitalization of $36.56 million, a price-to-earnings ratio of -2.60 and a beta of 1.93. The company has a current ratio of 4.22, a quick ratio of 4.22 and a debt-to-equity ratio of 0.51. The firm has a 50 day simple moving average of $1.86. Celsion has a 12-month low of $1.35 and a 12-month high of $3.11.

Celsion (NASDAQ:CLSN) last released its earnings results on Wednesday, May 15th. The biotechnology company reported ($0.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.25) by ($0.01). Celsion had a negative net margin of 1,954.60% and a negative return on equity of 65.35%. The business had revenue of $0.13 million during the quarter, compared to the consensus estimate of $0.13 million. On average, equities research analysts anticipate that Celsion will post -1.04 earnings per share for the current year.

An institutional investor recently raised its position in Celsion stock. BlackRock Inc. increased its stake in Celsion Co. (NASDAQ:CLSN) by 21.9% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 142,426 shares of the biotechnology company’s stock after purchasing an additional 25,548 shares during the quarter. BlackRock Inc. owned approximately 0.76% of Celsion worth $202,000 as of its most recent filing with the Securities and Exchange Commission. 4.76% of the stock is currently owned by institutional investors and hedge funds.

Celsion Company Profile

Celsion Corporation, a development stage oncology drug company, focuses on the development and commercialization of directed chemotherapies, DNA-mediated immunotherapy, and RNA based therapies for the treatment of cancer. Its lead product candidate is ThermoDox, a liposomal encapsulation of doxorubicin that is in Phase III clinical trial for treating primary liver cancer.

Recommended Story: What is a trade deficit?

Get a free copy of the Zacks research report on Celsion (CLSN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Celsion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celsion and related companies with MarketBeat.com's FREE daily email newsletter.